CORNOVUS PHARMACEUTICALS, INC.
Small-molecule P2X4 receptor antagonist drug candidate for ischemic stroke
- Sector
- Biotech
- Headquarters
- FARMINGTON, CT
- Founded
- 2011
- Latest Form D
- $500K, Jan 2024
- Total capital
- $7.5M
- Federal grants
- $4.5M
- 5 awards · 2020–2025
- Rank in peer group#198 of 514
- Private capital raised
- $3.1M
- 3 Form D · last Jan 2024
- 33 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A New Anti-inflammatory Therapy for Ischemic Stroke$1.1M
- Federal grantHealth and Human S · Phase II · A New Anti-inflammatory Therapy for Ischemic Stroke$935K
- Private capital raisedForm D · SEC · 3rd filing$500K
- Federal grantHealth and Human S · Phase II · A New Drug Therapy for Advanced Heart Failure$1M
- Federal grantHealth and Human S · Phase I · A New Anti-inflammatory Therapy for Ischemic Stroke$433K
- Federal grantHealth and Human S · Phase II · A New Drug Therapy for Advanced Heart Failure$969K
- Private capital raisedForm D · SEC · 2nd filing$983K
- Private capital raisedForm D · SEC · 1st filing$1.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#198 · top 39%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Bruce LiangResearcherDirectorLinked by $2.5M in grants as PI
- Daniel WagnerDirectorNamed in SEC Form D filings
- Glenn MattesExecutive Officer, DirectorNamed in SEC Form D filings
- Raymond NeagDirectorNamed in SEC Form D filings
- Robert Mark Van AllenExecutive OfficerNamed in SEC Form D filings
- R. Mark Van AllenExecutive OfficerNamed in SEC Form D filings
Show all 7 people
- Timothy ShannonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingCrystalline Forms And Salt Forms Of A Cardiac P2X Receptor Agonist, Pharmaceutical Compositions, And Their Use In Treating Medical DisordersUSPTOApplication 19226237
- PendingAqueous Formulations Of A Cardiac P2X Receptor Agonist And Their Use In Treating Medical DisordersUSPTOApplication 18778671
- PendingCrystalline Forms And Salt Forms Of A Cardiac P2X Receptor Agonist, Pharmaceutical Compositions, And Their Use In Treating Medical DisordersUSPTOApplication PCTUS2025031992
Show all 5 patent records
- Crystalline Forms And Salt Forms Of A Cardiac P2X Receptor Agonist, Pharmaceutical Compositions, And Their Use In Treating Medical DisordersDec 4, 2025 · Application 19226237Pending
- Aqueous Formulations Of A Cardiac P2X Receptor Agonist And Their Use In Treating Medical DisordersFeb 13, 2025 · Application 18778671Pending
- Crystalline Forms And Salt Forms Of A Cardiac P2X Receptor Agonist, Pharmaceutical Compositions, And Their Use In Treating Medical DisordersApplication PCTUS2025031992Pending
- Aqueous Formulations Of A Cardiac P2X Receptor Agonist And Their Use In Treating Medical DisordersApplication PCTUS2024038844Pending
- Crystalline Forms And Salt Forms Of A Cardiac P2X Receptor Agonist, Pharmaceutical Compositions, And Their Use In Treating Medical DisordersApplication 63655312Pending
Related companies, and why
- Compass TherapeuticsSimilar federal contract value in Biotech · null in contracts
- STINGRAY THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- IONCOLOGI INCSimilar federal contract value in Biotech · null in contracts
- APREA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- COURAGENE, INC.Similar federal contract value in Biotech · null in contracts
- SUNFLOWER THERAPEUTICS PBCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .